Brokerages Set AMAG Pharmaceuticals, Inc. (AMAG) Target Price at $21.64
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has earned an average rating of “Hold” from the nineteen brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $21.64.
A number of equities analysts have commented on the company. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Wednesday, October 4th. Morgan Stanley started coverage on AMAG Pharmaceuticals in a research report on Friday, September 8th. They issued an “overweight” rating and a $26.00 price target for the company. Cantor Fitzgerald restated a “hold” rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Finally, Piper Jaffray Companies started coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price target for the company.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded down $0.25 during trading on Tuesday, hitting $14.55. The company’s stock had a trading volume of 619,089 shares, compared to its average volume of 880,250. AMAG Pharmaceuticals has a fifty-two week low of $11.93 and a fifty-two week high of $36.60. The firm has a market capitalization of $513.45, a PE ratio of -2.39 and a beta of 0.79. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.